Interv Akut Kardiol. 2016;15(1):45-50 | DOI: 10.36290/kar.2016.012

Overview of antiplatelet and anticoagulant therapy after acute myocardial infarction

Marian Levčík, Jiří Kettner

Kardiologická klinika, IKEM, Praha

Currently, combined antiplatelet therapy is the mainstay of long-term pharmacotherapy in patients after acute myocardial infarction

(AMI). It consists of acetylsalicylic acid and one of the platelet P2Y12 receptor inhibitors, and is referred to as dual antiplatelet

therapy (DAPT). Newer and more efficacious agents, such as ticagrelor and prasugrel, are preferred; however, in some indications,

clopidogrel is still recommended. Patients in whom long-term anticoagulant therapy is indicated and who have suffered a

myocardial infarction are recommended to use a combination of DAPT and an anticoagulant drug. The long-dominant warfarin

is gradually being replaced with novel agents inhibiting thrombin or factor Xa (NOAC – novel oral anticoagulants). The aim of

this paper is to summarise the currently recommended long-term antithrombotic treatments after AIM and combinations with

anticoagulant therapy where indicated.

Keywords: P2Y12 inhibitors, NOAC, triple therapy

Published: February 1, 2016  Show citation